Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ASEP Medical HoldingsSEPSF 19 Return-on-Tangible-Equity is 0.00% as of Mar. 2026. GuruFocus rates SEPSF with a GF Score™ of 19/100. The stock has 4 warning signs investors should review. Among 1,200 Biotechnology companies, ASEP Medical Holdings ranks worse than 83333.25% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. ASEP Medical Holdings's annualized net income for the quarter that ended in Mar. 2026 was $-0.80 Mil. ASEP Medical Holdings's average shareholder tangible equity for the quarter that ended in Mar. 2026 was $-3.23 Mil. Therefore, ASEP Medical Holdings's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2026 was N/A%.
The historical rank and industry rank for ASEP Medical Holdings's Return-on-Tangible-Equity or its related term are showing as below:
SEPSF's Return-on-Tangible-Equity is not ranked *
in the Biotechnology industry.
Industry Median: -42.305 * Ranked among companies with meaningful Return-on-Tangible-Equity only.
ASEP Medical Holdings (OTCPK:SEPSF) Return-on-Tangible-Equity Explanation
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
ASEP Medical Holdings Return-on-Tangible-Equity Related Terms
ASEP Medical Holdings Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for ASEP Medical Holdings's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASEP Medical Holdings Return-on-Tangible-Equity Chart
SEPSF vs VRTX, REGN, ALNY: Return-on-Tangible-Equity Comparison
For the Biotechnology subindustry, ASEP Medical Holdings's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ASEP Medical Holdings Return-on-Tangible-Equity vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, ASEP Medical Holdings's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where ASEP Medical Holdings's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 0.00% mean?
ASEP Medical Holdings (SEPSF) has a Return-on-Tangible-Equity of 0.00% as of Mar. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on ASEP Medical Holdings and its competitors. According to the industry distribution chart, ASEP Medical Holdings ranks #999999 out of 1200 companies in the Biotechnology industry.
Is ASEP Medical Holdings' Return-on-Tangible-Equity too high?
ASEP Medical Holdings' current Return-on-Tangible-Equity is 0.00%. Based on the distribution chart, ASEP Medical Holdings ranks #999999 out of 1200 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, ASEP Medical Holdings has a GF Score™ of 19/100, reflecting its overall financial health beyond just this single metric.
How does ASEP Medical Holdings' Return-on-Tangible-Equity compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, ASEP Medical Holdings ranks #999999 out of 1200 companies for Return-on-Tangible-Equity. This places ASEP Medical Holdings in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Biotechnology company?
A good Return-on-Tangible-Equity depends on the Biotechnology industry context. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on ASEP Medical Holdings and its competitors. ASEP Medical Holdings's current Return-on-Tangible-Equity is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ASEP Medical Holdings stock overvalued right now?
ASEP Medical Holdings (SEPSF) has a current Return-on-Tangible-Equity of 0.00%. The current Return-on-Tangible-Equity is 0.00%. ASEP Medical Holdings' overall GF Score™ is 19/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For ASEP Medical Holdings (SEPSF), the current Return-on-Tangible-Equity is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
ASEP Medical Holdings Inc is in the business of acquiring research and development assets, technologies and/or businesses in the area of life sciences and medical diagnostics. Diagnostic and therapeutic solutions represent tremendous clinical and commercial potential, through rapid diagnostics and uniquely effective treatments. Its Diagnostic has developed a novel diagnostic assay for the early and rapid risk assessment of sepsis. Therapeutic offering: Patented peptide technology targets infection-causing biofilms and reduces inflammation.
19GF Score
Get the complete analysis for SEPSF
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SEPSF has been successfully added to your 
